In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Biolinerx (NASDAQ: BLRX), with a price target of $4. The company’s shares opened today at $0.94.
According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -9.8% and a 38.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Currently, the analyst consensus on Biolinerx is Strong Buy and the average price target is $3, representing a 219.1% upside.
In a report issued on May 17, Maxim Group also assigned a Buy rating to the stock with a $2 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $1.34 and a one-year low of $0.78. Currently, Biolinerx has an average volume of 245.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioLineRx Ltd. is a clinical-stage biopharmaceutical company, which includes indentifying, in-licensing, and developing therapeutic candidates. Its in-licenses novel compounds, primarily from academic institutions and biotech companies based in Israel, and develops them through pre-clinical and clinical stages, and then partners with pharmaceutical companies clinical development and commercialization. The company was founded in April 2003 and is headquartered in Modi’in, Israel.
